Hydroxychloroquin Aristo

Hydroxychloroquine, the active ingredient in Hydroxychloroquin Aristo, is an antimalarial presented as an oral tablet for oral use. It is employed in the prevention and treatment of malaria and in the management of autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus.

GNH USA supplies Hydroxychloroquin Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Hydroxychloroquine acts on malaria parasites and modulates immune activity in autoimmune diseases. - Malaria prophylaxis and treatment: prevents infection and clears parasites in confirmed cases. - Rheumatoid arthritis: reduces joint inflammation and disease progression. - Systemic lupus erythematosus: helps control disease activity and flares.

Hydroxychloroquine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or upset stomach. - Headache. - Diarrhea. - Skin rash or itching. - Visual disturbances such as blurred vision.

Serious or Rare Side Effects: - Retinopathy, potentially leading to permanent vision loss. - Cardiac toxicity, including cardiomyopathy and arrhythmias. - Severe hypoglycemia, especially in diabetic patients. - Blood dyscrasias such as agranulocytosis or thrombocytopenia.

Hydroxychloroquine requires careful monitoring to minimize risks. - Monitor retinal health: schedule regular ophthalmologic examinations. - Assess cardiac function: obtain baseline ECG and monitor for QT prolongation. - Check blood glucose levels: watch for hypoglycemia, especially when combined with antidiabetic agents. - Avoid use in patients with known hypersensitivity to 4‑aminoquinoline compounds. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Hydroxychloroquine can interact with several medication classes, affecting safety and efficacy.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce hydroxychloroquine absorption. - QT‑prolonging drugs (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias. - Strong CYP450 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: may potentiate hypoglycemic effect. - Warfarin: potential increase in anticoagulant activity. - Protease inhibitors (e.g., ritonavir): may alter drug metabolism and levels.